Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 2003;63:756–9.
Google ScholarÂ
Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681–96.
Rajkumar S, Watson IR. Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. Br J Cancer. 2016;115:145–55.
Google ScholarÂ
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.
Google ScholarÂ
Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012;18:1503–10.
Google ScholarÂ
Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62:6997–7000.
Google ScholarÂ
Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809–19.
Google ScholarÂ
Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867–76.
Google ScholarÂ
U.S. Food and Drug Administration. COTELLIC (cobimetinib) tablets, for oral use: Prescribing Information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206192s005lbl.pdf (accessed 2025-12-17).
Welsh SJ, Rizos H, Scolyer RA, Long GV. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: where to next? Eur J Cancer. 2016;62:76–85.
Google ScholarÂ
Sullivan RJ, Hollebecque A, Flaherty KT, Shapiro GI, Rodon Ahnert J, Millward MJ, et al. A phase I study of LY3009120, a Pan-RAF inhibitor, in patients with advanced or metastatic cancer. Mol Cancer Ther. 2020;19:460–7.
Google ScholarÂ
Fernandez MF, Choi J, Sosman J. New approaches to targeted therapy in melanoma. Cancers. 2023;15:3224.
Janku F, Kim TM, Iyer G, Spreafico A, Elez E, de Jonge M, et al. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. Eur J Cancer. 2024;196:113458.
Google ScholarÂ
Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13:828–51.
Google ScholarÂ
Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384:2371–81.
Google ScholarÂ
Awad, Liu MM, Rybkin II S, Arbour KC, Dilly J, Zhu VW, et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N Engl J Med. 2021;384:2382–93.
Google ScholarÂ
Isermann T, Sers C, Der CJ, Papke B. KRAS inhibitors: resistance drivers and combinatorial strategies. Trends Cancer. 2025;11:91–116.
Google ScholarÂ
Holderfield M, Lee BJ, Jiang J, Tomlinson A, Seamon KJ, Mira A, et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature. 2024;629:919–26.
Google ScholarÂ
Jiang J, Jiang L, Maldonato BJ, Wang Y, Holderfield M, Aronchik I, et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 2024;14:994–1017.
Google ScholarÂ
Aust O, Thiel MRT, Blanc E, Luthen M, Hollek V, Astaburuaga-Garcia R, et al. Reporter-based screening identifies RAS-RAF mutations as drivers of resistance to active-state RAS inhibitors in colorectal cancer. Sci Signal. 2025;18:eadr3738.
Google ScholarÂ
Sang B, Ye LF, Hu F, Pourfarjam Y, Cuevas-Navarro A, Fan S et al. Mechanisms of resistance to active state selective tri-complex RAS inhibitors. bioRxiv. 2025; https://doi.org/10.1101/2025.04.24.649345.
Jeon H, Tkacik E, Eck MJ. Signaling from RAS to RAF: the molecules and their mechanisms. Annu Rev Biochem. 2024;93:289–316.
Google ScholarÂ
Terrell EM, Morrison DK. Ras-mediated activation of the Raf family kinases. Cold Spring Harb Perspect Med. 2019;9:a033746.
Warne PH, Viciana PR, Downward J. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature. 1993;364:352–5.
Google ScholarÂ
Tran TH, Chan AH, Young LC, Bindu L, Neale C, Messing S, et al. KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation. Nat Commun. 2021;12:1176.
Google ScholarÂ
Cutler RE Jr., Stephens RM, Saracino MR, Morrison DK. Autoregulation of the Raf-1 serine/threonine kinase. Proc Natl Acad Sci USA. 1998;95:9214–9.
Google ScholarÂ
Kubicek M, Pacher M, Abraham D, Podar K, Eulitz M, Baccarini M. Dephosphorylation of Ser-259 regulates Raf-1 membrane association. J Biol Chem. 2002;277:7913–9.
Google ScholarÂ
Luo Z, Tzivion G, Belshaw PJ, Vavvas D, Marshall M, Avruch J. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature. 1996;383:181–5.
Google ScholarÂ
Dhillon AS, Meikle S, Yazici Z, Eulitz M, Kolch W. Regulation of Raf-1 activation and signalling by dephosphorylation. EMBO J. 2002;21:64–71.
Google ScholarÂ
Freeman AK, Ritt DA, Morrison DK. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol Cell. 2013;49:751–8.
Google ScholarÂ
cBioPortal for Cancer Genomics. Skin Cutaneous Melanoma (TCGA, PanCancer Atlas). 2025. https://www.cbioportal.org/study?id=skcm_tcga_pan_can_atlas_2018 (accessed 2025-10).
Wang P, Laster K, Jia X, Dong Z, Liu K. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities. Mol Cancer. 2023;22:208.
Google ScholarÂ
Riaud M, Maxwell J, Soria-Bretones I, Dankner M, Li M, Rose AAN. The role of CRAF in cancer progression: from molecular mechanisms to precision therapies. Nat Rev Cancer. 2024;24:105–22.
Google ScholarÂ
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.
Google ScholarÂ
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.
Google ScholarÂ
Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet. 2007;39:1007–12.
Google ScholarÂ
Razzaque MA, Nishizawa T, Komoike Y, Yagi H, Furutani M, Amo R, et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet. 2007;39:1013–7.
Google ScholarÂ
Molzan M, Schumacher B, Ottmann C, Baljuls A, Polzien L, Weyand M, et al. Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling. Mol Cell Biol. 2010;30:4698–711.
Google ScholarÂ
Antony R, Emery CM, Sawyer AM, Garraway LA. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res. 2013;73:4840–51.
Google ScholarÂ
Imielinski M, Greulich H, Kaplan B, Araujo L, Amann J, Horn L, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124:1582–6.
Google ScholarÂ
Louveau B, Jouenne F, Tetu P, Sadoux A, Gruber A, Lopes E, et al. A melanoma-tailored next-generation sequencing panel coupled with a comprehensive analysis to improve routine melanoma genotyping. Target Oncol. 2020;15:759–71.
Google ScholarÂ
Barbieux S, Jouenne F, Machet MC, Fraitag S, Macagno N, Battistella M, et al. Re-evaluation of the concept of basaloid follicular hamartoma associated with naevoid basal cell carcinoma syndrome: a morphological, immunohistochemical and molecular study. Pathology. 2025;57:49–56.
Google ScholarÂ
Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464:427–30.
Google ScholarÂ
Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464:431–5.
Google ScholarÂ
Hu J, Stites EC, Yu H, Germino EA, Meharena HS, Stork PJS, et al. Allosteric activation of functionally asymmetric RAF kinase dimers. Cell. 2013;154:1036–46.
Google ScholarÂ
Bennett DC, Cooper PJ, Hart IR. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer. 1987;39:414–8.
Google ScholarÂ
Yang Y, Wu J, Demir A, Castillo-Martin M, Melamed RD, Zhang G, et al. GAB2 induces tumor angiogenesis in NRAS-driven melanoma. Oncogene. 2013;32:3627–37.
Google ScholarÂ
Chiloeches A, Mason CS, Marais R. S338 phosphorylation of Raf-1 is independent of phosphatidylinositol 3-kinase and Pak3. Mol Cell Biol. 2001;21:2423–34.
Google ScholarÂ
Diaz B, Barnard D, Filson A, MacDonald S, King A, Marshall M. Phosphorylation of Raf-1 serine 338-serine 339 is an essential regulatory event for Ras-dependent activation and biological signaling. Mol Cell Biol. 1997;17:4509–16.
Google ScholarÂ
Jaumot M, Hancock JF. Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions. Oncogene. 2001;20:3949–58.
Google ScholarÂ
Dhillon AS, Pollock C, Steen H, Shaw PE, Mischak H, Kolch W. Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol Cell Biol. 2002;22:3237–46.
Google ScholarÂ
Medina M, Avila J, Villanueva N. Use of okadaic acid to identify relevant phosphoepitopes in pathology: a focus on neurodegeneration. Mar Drugs. 2013;11:1656–68.
Google ScholarÂ
Farrar MA, Alberol- IlaJ, Perlmutter RM. Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization. Nature. 1996;383:178–81.
Google ScholarÂ
Noeparast A, Giron P, Noor A, Bahadur Shahi R, De Brakeleer S, Eggermont C, et al. CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition. Oncogene. 2019;38:5933–41.
Google ScholarÂ
Atefi M, Titz B, Tsoi J, Avramis E, Le A, Ng C, et al. CRAF R391W is a melanoma driver oncogene. Sci Rep. 2016;6:27454.
Google ScholarÂ
King AJ, Sun H, Diaz B, Barnard D, Miao W, Bagrodia S, et al. The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature. 1998;396:180–3.
Google ScholarÂ
Chan EY, Stang SL, Bottorff DA, Stone JC. Mutations in conserved regions 1, 2, and 3 of Raf-1 that activate transforming activity. Mol Carcinog. 2002;33:189–97.
Google ScholarÂ
Nassar N, Horn G, Herrmann C, Scherer A, McCormick F, Wittinghofer A. The 2.2 A crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue. Nature. 1995;375:554–60.
Google ScholarÂ
Cregg J, Edwards AV, Chang S, Lee BJ, Knox JE, Tomlinson ACA, et al. Discovery of daraxonrasib (RMC-6236), a potent and orally bioavailable RAS(ON) multi-selective, noncovalent tri-complex inhibitor for the treatment of patients with multiple RAS-addicted cancers. J Med Chem. 2025;68:6064–83.
Google ScholarÂ
Schulze CJ, Seamon KJ, Zhao Y, Yang YC, Cregg J, Kim D, et al. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science. 2023;381:794–9.
Google ScholarÂ
Burd CE, Liu W, Huynh MV, Waqas MA, Gillahan JE, Clark KS, et al. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Discov. 2014;4:1418–29.
Google ScholarÂ
Park E, Rawson S, Schmoker A, Kim BW, Oh S, Song K, et al. Cryo-EM structure of a RAS/RAF recruitment complex. Nat Commun. 2023;14:4580.
Google ScholarÂ
Anastacio Da Costa Carvalho L, Tovbis Shifrin N, Phadke MS, Emmons MF, Pechuan-Jorge X, Mbuga F, et al. RAS(ON) multiselective inhibition drives antitumor immunity in preclinical models of NRAS-mutant melanoma. Cancer Immunol Res. 2026;14:90–106.
Google ScholarÂ
Ozgu E, Aydin E, Adibi A, Tokat UM, Tutar O, Hu J, et al. Exceptional response to MEK inhibition in a patient with RAF1-mutant myxofibrosarcoma: case report and mechanistic overview. JCO Precis Oncol. 2023;7:e2300299.
Google ScholarÂ
Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, et al. Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer. N Engl J Med. 2026;394:1790–802.
Google ScholarÂ
